A Phase II Study of Irinotecan HCI [hydrochloride] in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas.
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Irinotecan (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 11 Dec 2011 Actual patient number is 10 according to ClinicalTrials.gov.
- 11 Dec 2011 Planned end date changed from 1 Dec 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 11 Dec 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.